FBRX Forte Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FBRX

Price (delayed)

$0.4626

Market cap

$16.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.24

Enterprise value

-$29.38M

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and ...

Highlights
FBRX's quick ratio has dropped by 68% year-on-year but it is up by 28% since the previous quarter
The equity has soared by 62% from the previous quarter but it has contracted by 6% YoY
The net income has plunged by 147% YoY and by 27% from the previous quarter
FBRX's EPS has shrunk by 61% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fortebiorx.com
Peers: OMGA

Key stats

What are the main financial stats of FBRX
Market
Shares outstanding
36.34M
Market cap
$16.81M
Enterprise value
-$29.38M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$30.48M
EBITDA
-$30.48M
Free cash flow
-$22.7M
Per share
EPS
-$1.24
Free cash flow per share
-$0.6
Book value per share
$1.11
Revenue per share
$0
TBVPS
$1.26
Balance sheet
Total assets
$47.88M
Total liabilities
$7.47M
Debt
$0
Equity
$40.41M
Working capital
$39.63M
Liquidity
Debt to equity
0
Current ratio
6.3
Quick ratio
6.18
Net debt/EBITDA
1.52
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-77.3%
Return on equity
-89%
Return on invested capital
N/A
Return on capital employed
-75.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FBRX stock price

How has the Forte Biosciences stock price performed over time
Intraday
3.63%
1 week
6.96%
1 month
-6.96%
1 year
-52.8%
YTD
-53.74%
QTD
-30.12%

Financial performance

How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.04M
Net income
-$30.48M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 153% YoY and by 28% from the previous quarter
The net income has plunged by 147% YoY and by 27% from the previous quarter

Growth

What is Forte Biosciences's growth rate over time

Valuation

What is Forte Biosciences stock price valuation
P/E
N/A
P/B
0.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS has shrunk by 61% YoY and by 7% QoQ
The price to book (P/B) is 91% lower than the 5-year quarterly average of 4.6 and 40% lower than the last 4 quarters average of 0.7
The equity has soared by 62% from the previous quarter but it has contracted by 6% YoY

Efficiency

How efficient is Forte Biosciences business performance
FBRX's return on equity has dropped by 193% year-on-year and by 30% since the previous quarter
The company's return on assets has shrunk by 166% YoY and by 25% QoQ

Dividends

What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FBRX.

Financial health

How did Forte Biosciences financials performed over time
FBRX's quick ratio has dropped by 68% year-on-year but it is up by 28% since the previous quarter
The current ratio has dropped by 68% year-on-year but it has increased by 29% since the previous quarter
Forte Biosciences's debt is 100% less than its equity
The equity has soared by 62% from the previous quarter but it has contracted by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.